<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02602262</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00085148</org_study_id>
    <secondary_id>JHUHIVDD</secondary_id>
    <nct_id>NCT02602262</nct_id>
  </id_info>
  <brief_title>Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients</brief_title>
  <official_title>Observational Study of HIV+ Deceased Donor Solid Organ Transplant for HIV+ Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Methodist Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV-infected (HIV+) individuals who agree to accept and receive a solid organ transplant from
      an HIV+ deceased donor will be followed to determine the safety and efficacy of this
      practice. Some HIV+ individuals who receive a solid organ transplant from HIV-uninfected
      (HIV-) donors will also be followed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational study designed to evaluate safety and outcomes of solid organ
      transplantation in HIV+ recipients of HIV+ deceased donor organs. This study will evaluate
      overall survival and graft survival compared to transplantation with an HIV- organ.

      In addition the study will assess potential complications of organ transplant using HIV+
      deceased donors - including but not limited to - HIV superinfection, incidence and severity
      of graft rejection, recurrence of HIV-associated nephropathy, incidence of bacterial
      infections, and opportunistic infections.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>One year</time_frame>
    <description>Patient survival at one year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft survival</measure>
    <time_frame>one year, two years, 3 years, 4 years</time_frame>
    <description>Transplanted organ function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft rejection</measure>
    <time_frame>One year</time_frame>
    <description>Incidence and severity of organ rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV disease progression</measure>
    <time_frame>through study completion, up to 4 years</time_frame>
    <description>Incidence of virologic breakthrough or failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiretroviral resistance and X4 tropic virus</measure>
    <time_frame>through study completion, up to 4 years</time_frame>
    <description>incidence of new antiretroviral drug resistance and/or X4 tropic virus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of bacterial, fungal, viral, and other opportunistic infection</measure>
    <time_frame>through study completion, up to 4 years</time_frame>
    <description>incidence of bacterial, fungal, viral, and other opportunistic infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
    <time_frame>within the first 3 months</time_frame>
    <description>incidence of surgical and vascular transplant complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent HIV-associated nephropathy</measure>
    <time_frame>through study completion, up to 4 years</time_frame>
    <description>incidence of recurrent HIV-associated nephropathy in kidney recipients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-transplant Malignancy</measure>
    <time_frame>through study completion, up to 4 years</time_frame>
    <description>incidence of post-transplant malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of HIV superinfection in blood and/or tissue</measure>
    <time_frame>measured at 3 months, 6 months, year 1, year 2, year 3, year 4</time_frame>
    <description>Incidence of HIV superinfection in blood and/or tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV latent reservoir</measure>
    <time_frame>measured at 3 months, 6 months, year 1, year 2, year 3, year 4</time_frame>
    <description>Frequency of infected CD4 T cells in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune activation</measure>
    <time_frame>measured at 3 months, 6 months, year 1, year 2, year 3, year 4</time_frame>
    <description>Cytokine levels</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">425</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>HIV D+/R+</arm_group_label>
    <description>HIV-infected individuals who accept an organ from an HIV-infected deceased donor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV D-/R+</arm_group_label>
    <description>HIV-infected individuals who accept an organ from an HIV-uninfected deceased donor</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HIV-infected deceased donor organ</intervention_name>
    <description>HIV-infected deceased donor organ transplant</description>
    <arm_group_label>HIV D+/R+</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum, peripheral blood mononuclear cells, tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All individuals with end-stage organ disease and HIV infection who meet standard clinical
        criteria for transplantation and the study inclusion and exclusion criteria will be
        eligible for participation in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All individuals with end-stage organ disease and HIV infection who meet standard clinical
        criteria for transplantation and the study inclusion and exclusion criteria will be
        eligible for participation in the study.

          1. Participant is able to understand and provide informed consent

          2. Participant meets standard listing criteria for transplant.

          3. Documented HIV infection (by any licensed ELISA and confirmation by Western Blot,
             positive HIV Ab Immunofluorescence Assay (IFA), or documented history of detectable
             HIV-1 RNA).

          4. Participant is &gt; 18 years old.

          5. Opportunistic Complications: None or previous history of protocol allowed
             opportunistic infections or neoplasms with appropriate acute and maintenance therapy
             and no evidence of active disease.

          6. Participant CD4+ T-cell count is &gt;/= 200/ÂµL in the 16 weeks prior to transplant.

          7. Participant most recent HIV-1 RNA &lt; 50 copies/mL (by any FDA-approved assay performed
             in Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory) and on a
             stable antiretroviral regimen. Non-consecutive viral &quot;blips&quot; between 50-400 copies
             RNA/mL will be allowed. The Federal Register HIV Organ Policy Equity (HOPE) Act Final
             Safeguards and Research criteria does not specify a required frequency of HIV-1 RNA
             monitoring to determine recipient eligibility. The most recent HIV Viral Load (VL)
             should be &lt; 50 copies, but this result can be documented outside the 16 week window
             according to the judgement of the local clinical team and site investigator. Organ
             recipients who are unable to tolerate Antiretroviral Therapy (ART) due to organ
             failure or who have only recently started ART may have detectable viral load and still
             be considered eligible if the study team is confident there will be a safe, tolerable,
             and effective antiretroviral regimen to be used by the recipient once organ function
             is restored after transplantation.

          8. Participant is willing to use Pneumocystis Carinii Pneumonia (PCP), herpes virus and
             fungal prophylaxis as indicated.

        Exclusion Criteria:

          1. Participant has concomitant conditions that, in the judgment of the investigators,
             would preclude transplantation or immunosuppression.

          2. Opportunistic Complication History: Any history of progressive multifocal
             leukoencephalopathy (PML), chronic intestinal cryptosporidiosis of &gt; 1 month duration,
             or primary Central Nervous System (CNS) lymphoma.

          3. Participant has a history of any neoplasm except for the following: resolved Kaposi's
             sarcoma, in situ anogenital carcinoma, adequately treated basal or squamous cell
             carcinoma of the skin, solid tumors (except primary CNS lymphoma) treated with
             curative therapy and disease free for more than 5 years. History of renal cell
             carcinoma requires disease free state for 2 years. History of leukemia and
             disease-free duration will be per site policy.

          4. Participant is pregnant or breastfeeding. Note: Participants who become pregnant
             post-transplant will continue to be followed in the study and will be managed per
             clinical practice. Women that become pregnant should not breastfeed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Durand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dorry Segev, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Durand, MD</last_name>
    <phone>410-955-5684</phone>
    <email>cdurand2@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dorry Segev, MD, PhD</last_name>
    <phone>410-502-6115</phone>
    <email>dorry@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado, Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maheen Abidi, MD</last_name>
      <phone>303-724-4930</phone>
      <email>maheen.abidi@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Maheen Abidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maricar Malinis, MD</last_name>
      <phone>203-785-2073</phone>
      <email>maricar.malinis@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ricarda Tomlin</last_name>
      <phone>203-785-2073</phone>
      <email>ricarda.tomlin@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Maricar Malinis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Gilbert, MD</last_name>
      <phone>202-444-3700</phone>
      <email>alexander.j.gilbert@gunet.georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Alexander Gilbert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Turgeon, MD</last_name>
      <phone>404-727-3257</phone>
      <email>nturgeo@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Nicole Turgeon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Stosor, MD</last_name>
      <phone>312-695-5085</phone>
      <email>v-stosor@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Valentina Stosor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Santos, MD, MPHS</last_name>
      <phone>312-942-5864</phone>
      <email>carlos_a_santos@rush.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mark Mall, RN</last_name>
      <phone>312-942-5865</phone>
      <email>mark_mall@rush.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Santos, MD, MPHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Spaggiari, MD</last_name>
      <phone>312-675-9570</phone>
      <email>mspaggia@uic.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patricia West-Thielke, PharmD</last_name>
      <phone>312-533-1390</phone>
      <email>pwest@uic.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mario Spaggiari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oluwafisayo Adebiyi, MD</last_name>
      <phone>317-944-4370</phone>
      <email>olabiy@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Oluwafisayo Adebiyi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Amoroso, MD</last_name>
      <phone>410-706-4607</phone>
      <email>aamoroso@ihv.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Husson, MD, MPH</last_name>
      <phone>410-706-8614</phone>
      <email>jhusson@ihv.umaryland.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony Amoroso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Durand, MD</last_name>
      <phone>410-955-5684</phone>
      <email>cdurand2@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Diane Brown, RN, MSN</last_name>
      <phone>410-614-0648</phone>
      <email>dbrown22@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christine Durand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dorry Segev, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sapna Mehta, MD</last_name>
      <phone>646-754-1006</phone>
      <email>sapna.mehta@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Sapna Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sander Florman, MD</last_name>
      <phone>212-659-8313</phone>
      <email>sander.florman@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Shirish Huprikar, MD</last_name>
      <email>shirish.huprikar@mountsinai.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sander Florman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Falo, PhD</last_name>
      <phone>212-305-3839</phone>
      <email>cf2427@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Marcus Pereira, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thangamani Muthukumar, MD</last_name>
      <phone>212-746-4430</phone>
      <email>mut9002@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Small, MD</last_name>
      <phone>914-552-5960</phone>
      <email>cbs9003@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thangamani Muthukumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghady Haidar, MD</last_name>
      <phone>412-648-6212</phone>
      <email>haidarg@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Fernanda Silveira, MD</last_name>
      <phone>412-648-6512</phone>
      <email>silvfd@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ghady Haidar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Health System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose A. Castillo-Lugo, MD</last_name>
      <phone>214-358-2300</phone>
      <email>castilloj@dneph.com</email>
    </contact>
    <investigator>
      <last_name>Jose A. Castillo-Lugo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avinash Agarwal, MD</last_name>
      <phone>434-924-9370</phone>
      <email>AA4VB@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Avinash Agarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

